Exclusive research from the Public Sector Show 2018 takes the temperature of over 700 UK public servants, giving a picture of their views on the health of the nation’s public services.
The trend of wearable technology has been growing in healthcare, but one area that hasn’t been discussed much is diabetes. Each year more and more people live with diabetes which, if uncontrolled, can result in life-changing complications such as heart disease, nerve damage, kidney problems, and even death. According to the International Diabetes Foundation (IDF), there are 52 million people living with diabetes in Europe and by 2040, it is estimated that more than 72 million people will have the disease1.
Diabetes accounts for 10% of the NHS’s overall budget, and type 1 diabetes alone costs 2.7 million a day2, so the impact of technological solutions is not only front of mind for many people with type 1 diabetes (PWT1D), but also physicians and the government. There are many myths about diabetes that linger in public perception, from the belief that people with diabetes can’t drive or travel, to the false idea that they are unsuitable for certain jobs. Today, technology is helping patients and healthcare professionals better understand and manage diabetes.
Dexcom, Inc. is a healthcare technology company that develops and manufactures continuous glucose monitoring (CGM) systems that track a user’s glucose levels 24 hours a day. The Dexcom G5® Mobile CGM System replaces the need for finger pricks3 to make diabetes treatment decisions and provides continuous insight into glucose levels throughout the day and night. With almost 300 data points provided in 24 hours, the G5 Mobile helps provide greater glycaemic control – which is particularly important for people who have an impaired awareness of their glucose levels.
CGM technology is helping to manage the fastest growing health epidemic around the world. However, to safely benefit from these advances, it is essential that there is a clear clinical understanding of how and when to use them. In too many cases, the incorrect technology is being provided for those with an impaired awareness of hypoglycaemia, when real-time CGM with alerts would be more safe and effective. Studies have shown that real-time CGM systems with alerts help reduce time spent in hypoglycaemia, particularly in those with an impaired awareness of hypoglycaemia, whilst another popular option, flash glucose monitoring, tends to increase time spent in hypoglycaemia4.
Founded in 1999, Dexcom, Inc. has corporate offices in San Diego, California, EMEA headquarters in Edinburgh, Scotland and patients in 39 countries around the world. Dexcom is transforming diabetes care and management by providing life changing CGM technology. Since inception, the company has focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class—while empowering the community to take control of diabetes.
1). IDF Diabetes Atlas 7th Edition (2015)
2). Cost of Diabetes Report, Diabetes UK (2014)
3). If your glucose alerts and readings do not match your symptoms or expectations or you are taking medications containing paracetamol/acetaminophen, you should perform a finger prick to confirm your blood glucose level. A finger prick is needed every 12 hours to calibrate. LBL015792 Rev001
4). Reddy et al., Diabetic Medicine (2017)